C3 and PZP like alpha-2-macroglobulin domain containing 8Genealiases: ASGD8 · K-CAP · VIP
Q-omics provides the consensus-scored CPAMD8 profile across patient tissues and cancer cell-line models. CPAMD8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CPAMD8 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CPAMD8 RNA expression shows 17,498 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, KIRC, and CCRCC as cancer lineages where CPAMD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPAMD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPAMD8 survival associations across molecular data types. CPAMD8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPAMD8 RNA expression–survival associations across cancer types. High CPAMD8 expression shows unfavorable associations in LUSC, but favorable associations in HNSC, KIRC, MESO, LUAD and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CPAMD8 RNA expression.
This table summarizes CPAMD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CPAMD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPAMD8 shows lower tumor expression in KIRC, KICH, LUAD, KIRP, COAD and BRCA. The KIRC box plot shows higher CPAMD8 RNA expression in normal versus tumor tissue (log2 FC = −2.658, t-test p < 0.001).
This table shows molecular features associated with CPAMD8 in patient tissues and cancer cell lines. In patient samples, CPAMD8 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CPAMD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
